PET imaging of DNA damage using 89Zr-labelled anti-γH2AX-TAT immunoconjugates

PET imaging of DNA damage using 89Zr-labelled anti-γH2AX-TAT immunoconjugates

Show other versions (1)

© 2015, Springer-Verlag Berlin Heidelberg. Purpose: The efficacy of most anticancer treatments, including radiotherapy, depends on an ability to cause DNA double-strand breaks (DSBs). Very early during the DNA damage signalling process, the histone isoform H2AX is phosphorylated to form γH2AX. With...

Full description

Bibliographic Details
Main Authors:	Knight, J, Topping, C, Mosley, M, Kersemans, V, Falzone, N, Fernández-Varea, J, Cornelissen, B
Format:	Journal article
Published:	2015

Similar Items

PET imaging of DNA damage using (89)Zr-labelled anti-γH2AX-TAT immunoconjugates.
by: Knight, J, et al.
Published: (2015)

89Zr-anti-γH2AX-TAT allows early monitoring of response to gemcitabine and capecitabine therapy in pancreatic ductal adenocarcinoma
by: Knight, J, et al.
Published: (2016)

89Zr-anti-γH2AX-TAT but not 18F-FDG allows early monitoring of response to chemotherapy in a mouse model of pancreatic ductal adenocarcinoma
by: Knight, J, et al.
Published: (2017)

EP-2324: Non-invasive PET imaging of radiosensitive tumour regions using γH2AX-targeted immunoconjugate
by: Yaromina, A, et al.
Published: (2018)

Amplification of DNA damage by a γH2AX-targeted radiopharmaceutical.
by: Cornelissen, B, et al.
Published: (2012)

Amplification of DNA damage by a γH2AX-targeted radiopharmaceutical
by: Cornelissen, B, et al.
Published: (2012)

Imaging DNA damage in vivo using gammaH2AX-targeted immunoconjugates.
by: Cornelissen, B, et al.
Published: (2011)

Biodistribution and nuclear import of 111In-labeled HIV-1 tat peptide immunoconjugates after intravenous or intratumoural injection in tumour-bearing mice
by: Cornelissen, B, et al.
Published: (2006)

Comparative in vivo biodistribution of cells labelled with [89Zr]Zr-(oxinate)4 or [89Zr]Zr-DFO-NCS using PET
by: Ida Friberger, et al.
Published: (2023-08-01)

Cellular penetration and nuclear importation properties of 111In-labeled and 123I-labeled HIV-1 tat peptide immunoconjugates in BT-474 human breast cancer cells.
by: Cornelissen, B, et al.
Published: (2007)

Kinetics of internalization and nuclear import and efflux of 111In-and 123I-labeled HIV-1 tat-peptide immunoconjugates (IC's) in BT-474 human breast cancer cells
by: Cornelissen, B, et al.
Published: (2006)

111In-labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1.
by: Cornelissen, B, et al.
Published: (2009)

Development of 89Zr Labelled Radiopharmaceuticals
by: WANG Li-zhen;YANG Min
Published: (2016-10-01)

PET Imaging of Acidic Tumor Environment With 89Zr-labeled pHLIP Probes
by: David Bauer, et al.
Published: (2022-05-01)

Potential and pitfalls of 89Zr-immuno-PET to assess target status: 89Zr-trastuzumab as an example
by: Marc C. Huisman, et al.
Published: (2021-08-01)

Characterising In-111-anti-gamma H2AX-TAT in targeting the DNA damage signal associated with Wnt activated colorectal cancer
by: Konstantinou, M, et al.
Published: (2016)

Current Perspectives on <sup>89</sup>Zr-PET Imaging
by: Joon-Kee Yoon, et al.
Published: (2020-06-01)

Detection limit of 89Zr-labeled T cells for cellular tracking: an in vitro imaging approach using clinical PET/CT and PET/MRI
by: Laura M. Lechermann, et al.
Published: (2020-07-01)

Properties of [(111)In]-labeled HIV-1 tat peptide radioimmunoconjugates in tumor-bearing mice following intravenous or intratumoral injection.
by: Cornelissen, B, et al.
Published: (2008)

Monitoring Src status after dasatinib treatment in HER2+ breast cancer with 89Zr-trastuzumab PET imaging
by: Brooke N. McKnight, et al.
Published: (2018-10-01)

Can γH2AX be used to personalise cancer treatment?
by: Shah, K, et al.
Published: (2013)

<sup>89</sup>Zr-Labeled AR20.5: A MUC1-Targeting ImmunoPET Probe
by: Kimberly Fung, et al.
Published: (2020-05-01)

Biodistribution of 89Zr-DFO-labeled avian pathogenic Escherichia coli outer membrane vesicles by PET imaging in chickens
by: Zhe Li, et al.
Published: (2023-02-01)

Evaluation of the EPR Effect in the CAM-Model by Molecular Imaging with MRI and PET Using <sup>89</sup>Zr-Labeled HSA
by: Colmar Hilbrig, et al.
Published: (2023-02-01)

Targeted Therapy With Immunoconjugates for Multiple Myeloma
by: Wassilis S. C. Bruins, et al.
Published: (2020-06-01)

First-in-human immunoPET imaging of HIV-1 infection using 89Zr-labeled VRC01 broadly neutralizing antibody
by: Denis R. Beckford-Vera, et al.
Published: (2022-03-01)

Toward Optimized <sup>89</sup>Zr-Immuno-PET: Side-by-Side Comparison of [<sup>89</sup>Zr]Zr-DFO-, [<sup>89</sup>Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [<sup>89</sup>Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?
by: Helen Damerow, et al.
Published: (2022-10-01)

89Zr-Cobalamin PET Tracer: Synthesis, Cellular Uptake, and Use for Tumor Imaging
by: Akhila N. W. Kuda-Wedagedara, et al.
Published: (2017-10-01)

89Zr-leukocyte labelling for cell trafficking: in vitro and preclinical investigations
by: Maryke Kahts, et al.
Published: (2023-11-01)

Zirconium-89-labelled rituximab PET-CT in orbital inflammatory disease
by: Kamil G. Laban, et al.
Published: (2019-07-01)

89Zr-Labeled Multifunctional Liposomes Conjugate Chitosan for PET-Trackable Triple-Negative Breast Cancer Stem Cell Targeted Therapy
by: Yang R, et al.
Published: (2020-11-01)

Non-specific irreversible 89Zr-mAb uptake in tumours: evidence from biopsy-proven target-negative tumours using 89Zr-immuno-PET
by: Jessica E. Wijngaarden, et al.
Published: (2024-02-01)

Molecular radiotherapy using cleavable radioimmunoconjugates that target EGFR and γH2AX.
by: Cornelissen, B, et al.
Published: (2013)

How to obtain the image-derived blood concentration from 89Zr-immuno-PET scans
by: Jessica E. Wijngaarden, et al.
Published: (2024-02-01)

Experimental constraints on the γ-ray strength function in 90Zr using partial cross sections of the Y89(p,γ)Zr90 reaction
by: L. Netterdon, et al.
Published: (2015-05-01)

89Zr-PET imaging of DNA double-strand breaks for the early monitoring of response following α- and β-particle radioimmunotherapy in a mouse model of pancreatic ductal adenocarcinoma
by: Poty, S, et al.
Published: (2020)

89Zr-labeled ImmunoPET targeting the cancer stem cell antigen CD133 using fully-human antibody constructs
by: Kevin Wyszatko, et al.
Published: (2024-03-01)

89Zr-panitumumab PET imaging for preoperative assessment of ameloblastoma in a PDX model
by: Logan D. Stone, et al.
Published: (2022-11-01)

Feasibility of PET/CT system performance harmonisation for quantitative multicentre 89Zr studies
by: Andres Kaalep, et al.
Published: (2018-11-01)

In Vivo PET Imaging of Monocytes Labeled with [<sup>89</sup>Zr]Zr-PLGA-NH<sub>2</sub> Nanoparticles in Tumor and <i>Staphylococcus aureus</i> Infection Models
by: Massis Krekorian, et al.
Published: (2021-10-01)